Skip to content
Script Sermorelin

A developer-console reading of the sermorelin literature, laid out as a bento board — the GHRH(1-29) mechanism, the cognition and neuroendocrine evidence, and the honest data limits each given their own panel.

The papers behind each finding

Where can you check the Sermorelin studies?

Each bracket number leads to a paper on this page. You can open the link and read the study yourself.

Return to the studiesRead common questions

How do you find the paper behind a claim?

A small bracket number follows many claims. It works like a footnote in your morning paper. Match that bracket number below. Then open the study link.

The links go to a study page or an FDA page. Some entries also carry the paper's own search code. You can ignore that code unless you want to search another library.

The list begins with work from the 1990s. It covers IGF-1 blood tests, aging, thinking, animals, and cells in a dish. Reviews and rules from 2024-2026 appear near the end.

  1. Thorner M, Rochiccioli P, Colle M, Lanes R, Grunt J, Galazka A, Landy H, Eengrand P, Shah S. Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. J Clin Endocrinol Metab. 1996;81(3):1189-96. ↗
  2. Corpas E, Harman SM, Pineyro MA, Roberson R, Blackman MR. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. J Clin Endocrinol Metab. 1992;75(2):530-535. ↗
  3. Wilton P, Chardet Y, Danielson K, Widlund L, Gunnarsson R. Pharmacokinetics of growth hormone-releasing hormone(1-29)-NH2 and stimulation of growth hormone secretion in healthy subjects after intravenous or intranasal administration. Acta Paediatr Suppl. 1993;388:10-15. ↗
  4. Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging. 2006;1(4):307-308. ↗
  5. Blackman MR. Use of growth hormone secretagogues to prevent or treat the effects of aging: not yet ready for prime time. Ann Intern Med. 2008;149(9):677-9. ↗
  6. Baker LD, Barsness SM, Borson S, Merriam GR, Friedman SD, Craft S, Vitiello MV. Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial. Arch Neurol. 2012;69(11):1420-1429. NCT00257712. ↗
  7. Jaszberenyi M, Rick FG, et al. Beneficial effects of novel antagonists of GHRH in different models of Alzheimer's disease. Aging (Albany NY). 2012;4(11):755-67. ↗
  8. Telegdy G, Tanaka M, Schally AV. Effects of the growth hormone-releasing hormone (GH-RH) antagonist on brain functions in mice. Behav Brain Res. 2011;224(1):155-8. ↗
  9. Sáez JM. Possible usefulness of growth hormone/insulin-like growth factor-I axis in Alzheimer's disease treatment. Endocr Metab Immune Disord Drug Targets. 2012;12(3):274-86. ↗
  10. Lee H, et al. PEGylation of growth hormone-releasing hormone (GRF) analogues. Adv Drug Deliv Rev. 2003;55(10):1369-1377. ↗
  11. Muller EE, Locatelli V, Cocchi D. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr Rev. 1998;19(6):717-797. ↗
  12. Granata R, Leone S, Zhang X, Gesmundo I, Steenblock C, Cai R, Sha W, Ghigo E, Hare JM, Bornstein SR, Schally AV. Growth hormone-releasing hormone and its analogues in health and disease. Nat Rev Endocrinol. 2025;21(3):180-195. ↗
  13. Datta A, Ghosh B, et al. Mesenchymal stem cell therapy with GHRH receptor analog resolves post-stroke vasogenic edema via modulating AQP4 and mitochondria-ER crosstalk. J Transl Med. 2026;24. ↗
  14. Villar-Gouy KR, Salmon CEG, et al. Brain morphometry and estimation of aging brain in subjects with congenital untreated isolated GH deficiency. J Endocrinol Invest. 2024;47:2797-2807. ↗
  15. U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. FDA.gov; 2025. ↗
  16. Munafo A, Nguyen TX, Papasouliotis O, et al. Polyethylene glycol-conjugated growth hormone-releasing hormone is long acting and stimulates GH in healthy young and elderly subjects. European journal of endocrinology. 2005;153:249-56. ↗
  17. Chen RG, Shen YN, Yei J, et al. A comparative study of growth hormone (GH) and GH-releasing hormone(1-29)-NH2 for stimulation of growth in children with GH deficiency. Acta paediatrica (Oslo, Norway : 1992). Supplement. 1993;388:32-5; discussion 36. ↗
  18. Khorram O, Laughlin GA, Yen SS Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women. The Journal of clinical endocrinology and metabolism. 1997;82:1472-9. ↗
  19. Lanes R, Carrillo E Long-term therapy with a single daily subcutaneous dose of growth hormone releasing hormone (1-29) in prepubertal growth hormone deficient children. Venezuelan Collaborative Study Group. The Journal of pediatric endocrinology. 1994;7:303-8. ↗
  20. Gelander L, Lindstedt G, Selstam G, et al. Effects of acute intravenous injection of two growth hormone-releasing hormones (GHRH 1-40 and 1-29) on serum growth hormone and other pituitary hormones in short children with pulsatile growth hormone secretion. Hormone research. 1989;31:213-20. ↗
  21. Tauber MT, Pienkowski C, Pigeon P, et al. Growth hormone (GH) profiles in response to continuous subcutaneous infusion of GH-releasing hormone(1-29)-NH2 in children with GH deficiency. Acta paediatrica (Oslo, Norway : 1992). Supplement. 1993;388:28-30; discussion 31. ↗
  22. Coutinho LFD, DE Oliveira Neves LF, Camilo RP A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review. The Journal of sports medicine and physical fitness. 2026. ↗
  23. Mendias CL, Awan TM Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports medicine (Auckland, N.Z.). 2026. ↗
  24. Villegas Meza AD, et al. Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications. JBJS reviews. 2026;14. ↗
  25. Esposito S, et al. Advances in the detection of growth hormone releasing hormone synthetic analogs. Drug Test Anal. 2021. ↗
  26. Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999;12(2):139-157. ↗
  27. Ko FY, Chen WP, Lin CY Defective response of plasma growth hormone to growth hormone releasing factor in growth hormone deficient children. Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi. 1992;33:243-50. ↗
  28. Tuilpakov AN, et al. Growth hormone (GH)-releasing effects of synthetic peptide GH-releasing peptide-2 and GH-releasing hormone (1-29NH2) in children with GH insufficiency and idiopathic short stature. Metabolism. 1995;44:1199-204. ↗
  29. Yuen KC, Biller BM, Molitch ME, Cook DM. Clinical review: Is lack of recombinant growth hormone (GH)-releasing hormone in the United States a setback or time to consider glucagon testing for adult GH deficiency? J Clin Endocrinol Metab. 2009;94(8):2702-2707. ↗
  30. U.S. Food and Drug Administration Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the Federal Food, Drug, and Cosmetic Act (Guidance for Industry). FDA Guidance for Industry. 2025. ↗